MJMegan T. Jones

Megan T. Jones

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Megan T. Jones has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A living systematic review, meta-analysis, and open data resource of trials of MDMA-assisted therapy for PTSD

    by Brooke L. Sevchik, S. Parker Singleton, Analiese Lahey, Pim Cuijpers, Mathias Harrer, Megan T. Jones, Sandeep M. Nayak, Eric C. Strain, Simon N. Vandekar, David B. Yaden, et al.

    3,4-Methylenedioxymethamphetamine (MDMA) has emerged as a potential treatment for post-traumatic stress disorder (PTSD). However, rapidly changing evidence in a fast-moving field can be challenging to integrate. Here, we present a living systematic review and open-data meta-analytic resource on MDMA treatment for PTSD. In this initial release, 6 randomized controlled trials comprising 286 participants are included in the database. All six studies included in the review to date are sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS). Our primary model uses inverse-variance random-effects meta-analysis of standardized mean differences on primary outcomes of PTSD. Compared to control conditions, MDMA-assisted therapy (MDMA-AT) showed a greater reduction in PTSD symptoms (Hedges’ g = −0.71). Meta-regressions on dosing variables were explored. Treatment with MDMA-AT as compared to placebo also resulted in higher response (risk ratio [ RR ] = 1.35) and remission ( RR = 2.25) rates. Most studies included in the database had a low risk of bias according to Cochrane guidelines, though these fail to capture pertinent challenges in the field such as expectancy, functional unblinding, potential issues with study conduct, and safety. The current findings were assigned an overall low certainty rating using the GRADE approach. Together, this systematic review and meta-analysis suggests that MDMA-AT results in short-term decreases in PTSD symptoms across studies to date. This living systematic review, meta-analysis, database, and online dashboard ( sypres.io ) will continue to be updated as evidence emerges, providing a valuable, open, and transparent resource for researchers in a rapidly evolving field.

  • Open Access

    A living systematic review, meta-analysis, and open data resource of trials of MDMA-assisted therapy for PTSD

    by Brooke L. Sevchik, S. Parker Singleton, Analiese Lahey, Pim Cuijpers, Mathias Harrer, Megan T. Jones, Sandeep M. Nayak, Eric C. Strain, Simon N. Vandekar, David B. Yaden, et al.

    3,4-methylenedioxymethamphetamine (MDMA) has emerged as a potential treatment for post-traumatic stress disorder (PTSD), generating considerable enthusiasm in the field. However, rapidly changing evidence in a fast-moving field can be challenging to integrate. Here, we present a living systematic review and open-data meta-analytic resource on MDMA treatment for PTSD. In this initial release, six randomized controlled trials comprising 286 participants are included in the database. Our primary model uses inverse-variance random-effects meta-analysis of standardized mean differences on primary outcomes of PTSD. Compared to control conditions, MDMA showed a greater reduction in PTSD symptoms (Hedges’ g = -0.71). Meta-regression on both the number of dosing sessions and cumulative dose showed that a higher number of dosing sessions and a higher cumulative dose was related to larger effects of MDMA. Treatment with MDMA as compared to placebo also resulted in higher response (risk ratio ( RR ) = 1.35) and remission ( RR = 2.25) rates. Most studies included in the database had a low risk of bias according to Cochrane guidelines, though these fail to capture pertinent challenges in the field such as expectancy, functional unblinding, potential issues with study conduct, and safety. The current findings were assigned an overall low certainty rating using the GRADE approach. Together, this systematic review and meta-analysis suggests that MDMA-assisted therapy results in short-term decreases in PTSD symptoms across studies to date, though more trials are needed. This living systematic review, meta-analysis, database, and online dashboard ( sypres.io ) will continue to be updated as evidence emerges, providing a valuable, open, and transparent resource for researchers in a rapidly evolving field.

  • Open Access

    Improved Estimation of Correlation Accuracy for Machine Learning Brain-Phenotype Associations

    by Megan T Jones, Ishaan Gadiyar, Xinyu Zhang, Kaidi Kang, Jinyuan Liu, Andrew Chen, Jakob Seidlitz, Aaron Alexander-Bloch, Edward Kennedy, Simon Vandekar

    Machine learning is used in neuroscience to examine brain-phenotype associations and facilitate individual prediction from high-dimensional brain imaging. For continuous phenotypes, Pearson correlation between the observed and predicted phenotype is used to quantify model accuracy in testing data. However, recent research suggests millions of samples may be needed to reliably estimate the maximum achievable predictive accuracy (MAPA). We formally define the MAPA and show that the Pearson estimator is biased for this quantity and its confidence intervals fail to capture the target. We develop a semiparametric (double machine learning) one-step estimator that more accurately estimates the MAPA and yields valid confidence intervals across flexible machine learning settings. Analyzing data from the Reproducible Brain Charts dataset, we show that this estimator has smaller bias when estimating brain-phenotype associations of neuroimaging data with age and psychopathology phenotypes. We show that MAPA for psychopathology factor scores using machine learning models built on structural and functional imaging measures is not better than using demographic and nuisance covariates alone.


  • Open Access

    Psilocybin treatment for symptoms of depression: a living systematic review, meta-analysis, and data resource

    by S. Parker Singleton, Brooke L. Sevchik, Analiese Lahey, Pim Cuijpers, Mathias Harrer, Megan T. Jones, Sandeep M. Nayak, Eric C. Strain, Simon N. Vandekar, Robert H. Dworkin, et al.

    Importance: Depression is a major cause of disability worldwide, motivating substantial interest in psilocybin as a potential treatment. Objective: To conduct a systematic review and meta-analysis of psilocybin’s impact on depressive symptoms and provide a living open data resource. Data Sources: PubMed, Embase, Scopus, Web of Science, and PsycINFO retrieved by a systematic search up to July 1, 2025. Study Selection: We included randomized controlled trials of psilocybin or psilocybin-assisted therapy compared against a placebo or waitlist condition. Data Extraction and Synthesis: Data extraction was completed independently by two extractors. A random-effects meta-analysis was used to synthesize data. Risk of bias was assessed with Cochrane’s RoB 2.0 tool. Main Outcomes and Measures: The main outcome was the standardized mean difference (Hedges’ g ) in depression scores at the primary study endpoint. Results: Twelve studies comprising 711 participants were included in the database, with nine of those studies (n = 529) included in our primary model. Of the nine studies included in the primary model, two had a high risk of bias, four had some concerns, while three had a low risk of bias. Compared to control conditions, psilocybin showed a greater reduction in depression scores, with a pooled Hedges’ g = –0.91 (95% CI, [-1.35; –0.48]; k = 9; p = 0.0013, I 2 = 58.1%, tau 2 = 0.13, n = 501). Sensitivity analyses revealed robust effects consistent with the primary model across a variety of design parameters and analysis choices, while also suggesting that waitlist control and crossover design studies contribute a large amount of heterogeneity to the primary model. Meta-regression revealed that psilocybin’s effects were rapid and consistent over several weeks (intercept = –0.92 [-1.26; –0.58], p < 0.0001; slope = 0.0009 [-0.0023; 0.0041], p = 0.57). Conclusions and Relevance: This systematic review and meta-analysis suggests that psilocybin-assisted therapy results in substantial decreases in depressive symptoms across studies to date. However, many studies have small sample sizes or risk of bias. This living systematic review, meta-analysis, database, and online dashboard will continue to be updated as evidence emerges, providing a valuable resource for researchers in a rapidly evolving field. Key Points: Question: What is the efficacy of psilocybin or psilocybin-assisted therapy for depressive symptoms? Findings: In this living systematic review and meta-analysis, the initial evidence suggests that psilocybin is more effective in reducing depression symptoms compared to control conditions. Our publicly released database and interactive dashboard contains over 200 effect sizes from 12 randomized clinical trials testing psilocybin’s impacts on depression and will be updated regularly to keep pace with this rapidly moving field. Meaning: The current evidence suggests promise for psilocybin therapy for depression, though more studies are needed.


  • Top Cited Papers
    Open Access

    Study design features increase replicability in brain-wide association studies

    by Kaidi Kang, Jakob Seidlitz, Richard A. I. Bethlehem, Jiangmei Xiong, Megan T. Jones, Kahini Mehta, Arielle S. Keller, Ran Tao, Anita Randolph, Bart Larsen, et al.

    Brain-wide association studies (BWAS) are a fundamental tool in discovering brain–behaviour associations1,2. Several recent studies have shown that thousands of study participants are required for good replicability of BWAS1–3. Here we performed analyses and meta-analyses of a robust effect size index using 63 longitudinal and cross-sectional MRI studies from the Lifespan Brain Chart Consortium4 (77,695 total scans) to demonstrate that optimizing study design is critical for increasing standardized effect sizes and replicability in BWAS. A meta-analysis of brain volume associations with age indicates that BWAS with larger variability of the covariate and longitudinal studies have larger reported standardized effect size. Analysing age effects on global and regional brain measures from the UK Biobank and the Alzheimer’s Disease Neuroimaging Initiative, we showed that modifying study design through sampling schemes improves standardized effect sizes and replicability. To ensure that our results are generalizable, we further evaluated the longitudinal sampling schemes on cognitive, psychopathology and demographic associations with structural and functional brain outcome measures in the Adolescent Brain and Cognitive Development dataset. We demonstrated that commonly used longitudinal models, which assume equal between-subject and within-subject changes can, counterintuitively, reduce standardized effect sizes and replicability. Explicitly modelling the between-subject and within-subject effects avoids conflating them and enables optimizing the standardized effect sizes for each separately. Together, these results provide guidance for study designs that improve the replicability of BWAS.